Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRP2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $167,457
Award facts
- Contract value 100% obligated
- $167,457.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $167,457.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of January 5, 2026, and utilizes no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform work at its Park Ridge, Illinois location and will serve as the sole prime contractor with no identified subcontractor relationships.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical supplier within the broader $30.3 billion PPV-G GEN V acquisition strategy. This framework authorizes DLA to issue firm fixed-price delivery orders for diverse pharmaceutical products, biologics, and medical consumables to support Department of Defense healthcare operations globally, with the Keytruda delivery representing one of numerous orders demonstrating the contractor's established performance capability across specialized pharmaceutical requirements for military medical facilities.
Quick answers
Who was awarded contract SPE2DR26FCRP2?
SPE2DR26FCRP2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FCRP2 worth?
The government has obligated $167,457 on SPE2DR26FCRP2.
Is contract SPE2DR26FCRP2 an order under another contract?
Yes. SPE2DR26FCRP2 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRP2 competed?
The extent of competition for SPE2DR26FCRP2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award